An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .
Status:
Completed
Trial end date:
2010-11-24
Target enrollment:
Participant gender:
Summary
This study will be an open-label study to evaluate the effect of albiglutide on the
pharmacokinetics and pharmacodynamics of a standard oral contraceptive regimen (Brevicon).
The primary objective of this study is to demonstrate the lack of effect of albiglutide doses
on the pharmacokinetics of norethindrone and ethinyl estradiol in healthy female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Contraceptive Agents Contraceptives, Oral Glucagon-Like Peptide 1 Mestranol Norethindrone Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination Norinyl rGLP-1 protein